Belotecan clinical trials
Includes 1 study of Pegylated Liposomal Belotecan.
How each study uses belotecan is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
Studies by the year they started
8 studies that test it; most in 2009 (2)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 1 |
| 2011 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 3 · Other 5
Chong Kun Dang Pharmaceutical (3) · Chonnam National University Hospital (1) · Yonsei University (1) · University of Pittsburgh (1) · Sokbom Kang (1) · Gachon University Gil Medical Center (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses belotecan is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Trial of Belotecan/Cisplatin in Chemotherapy Naive Small Cell Lung Cancer PatientCompletedPhase 3Chonnam National University HospitalNCT00826644Written as Belotecan
- A Randomized Study to Compare the Efficacy and Safety of Belotecan and Topotecan as Monotherapy for Sensitive-Relapsed Small Cell Lung CancerCompletedPhase 2Chong Kun Dang PharmaceuticalNCT01497873Written as Belotecan
- Belotecan Versus Topotecan for Recurrent Ovarian Cancer: A Randomized, Open-label, Parallel-group Phase IIb TrialCompletedPhase 2Chong Kun Dang PharmaceuticalNCT01630018Written as Belotecan
- A Phase Ib/II Trial of Belotecan and Ifosfamide in Patients With Extensive Disease of Small Cell Lung CancerStatus unknownPhase 1/2Gachon University Gil Medical CenterNCT01784107Written as Belotecan and Ifosfamide
- Study of Camtobell Inj (Belotecan) on Weekly Schedule in Non-small Cell Lung Cancer (NSCLC) Patients Previously Treated With ChemotherapyCompletedPhase 2Chong Kun Dang PharmaceuticalNCT01022671Written as Belotecan
- Belotecan and Cisplatin in Treating Patients With Previously Untreated, Extensive-Stage Small Cell Lung CancerCompletedPhase 2Yonsei UniversityNCT00754858Written as belotecan hydrochloride
- Safety Study of S-CKD602 in Patients With Advanced MalignanciesCompletedPhase 1University of PittsburghNCT00177281Written as S CKD602
- Belotecan (CKD-602) in Recurrent or Progressive Carcinoma of Uterine CervixCompletedPhase 2Sokbom KangNCT00430144Written as Belotecan(CKD-602)
Codes
What other systems call belotecan · ClinicalTrials.gg INT004124
- MeSH (NLM) C116963belotecanConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 27Z82M2G1NBELOTECANConfirmed FDA, NLM, Wikidata
- Wikidata Q4884574belotecanConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C73305BelotecanOne source FDA
- DrugBank DB12459One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C116963 | belotecan | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 27Z82M2G1N | BELOTECAN | Confirmed FDA, NLM, Wikidata |
| Wikidata | Q4884574 | belotecan | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C73305 | Belotecan | One source FDA |
| DrugBank | DB12459 | — | One source Wikidata |
Also registered as belotecan hydrochloride (UNII 01DZ4127G7).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.